InvestorsHub Logo
Followers 827
Posts 119499
Boards Moderated 15
Alias Born 09/05/2002

Re: floblu14 post# 15699

Friday, 08/05/2016 4:30:56 PM

Friday, August 05, 2016 4:30:56 PM

Post# of 20689
MNTA continues to have strong liquidity:

https://www.sec.gov/Archives/edgar/data/1235010/000123501016000008/mnta0630201610q.htm#s0BCA1FD2CD8E594D92231793B023C9C1

The 6/30/16 pro forma cash balance was $369.7M; this consisted of: $336.9M of unrestricted cash and marketable securities; $35.9M of collaboration receivables from MYL relating to the companies’ FoB partnership; $20.7M of restricted cash (mostly related to the Lovenox patent case); less $23.8 in net current liabilities.

For the remainder of 2016, MNTA’s cash-usage guidance—excluding all revenue from NVS and SHPG, but taking into account R&D reimbursement from MYL—is $40-45M per quarter.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”